Back to News
Market Impact: 0.45
Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product
Source: marketbeat.com
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA granted accelerated approval to Inovio Pharmaceuticals’ VOCERYQ, formerly INO-3107, as a nonsurgical treatment intended to reduce surgery frequency in adults with recurrent respiratory papillomatosis. The approval is a positive regulatory milestone for the company; the article provides no sales outlook or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
INO0.85
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- How Trump’s trade policy is handing Asia to Beijing
- Apple outpaces sales expectations as it continues to battle surging memory chip costs